Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$10.80
-2.1%
$6.50
$4.92
$25.58
$5.91M1.34135,674 shs91,217 shs
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$1.33
0.0%
$1.74
$1.09
$7.67
$16.36M0.5350,939 shs12,343 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.30
$0.26
$0.10
$1.37
$13.48M1.21.57 million shs46,117 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.20
-0.3%
$1.17
$0.90
$1.88
$13.99M0.5516,865 shs18,695 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
+16.11%+78.65%+67.12%+104.03%+39.27%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
+0.02%+2.73%-28.67%-37.54%-75.41%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-5.81%+37.61%-16.64%+92.31%-75.21%
Synlogic, Inc. stock logo
SYBX
Synlogic
+2.12%+0.84%+1.09%+3.88%-15.73%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
2.9763 of 5 stars
3.65.00.00.02.40.00.6
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
4.5968 of 5 stars
3.55.00.04.33.81.70.0
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
1.0255 of 5 stars
0.03.00.00.02.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
3.20
Buy$33.00227.38% Upside
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
3.00
Buy$4.00195.42% Upside
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ARTL, NKGN, CASI, and SYBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/6/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
5/19/2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
4/28/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
4/9/2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $4.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/A$5.31 per shareN/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$28.54M0.58N/AN/A$0.12 per share11.28
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/A($2.68) per shareN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
$10K1,386.45N/AN/A$1.09 per share1.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$9.83M-$17.94N/AN/AN/AN/A-226.99%-164.61%8/12/2025 (Estimated)
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$39.26M-$2.55N/AN/A-129.05%-972.55%-77.33%8/15/2025 (Estimated)
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$2.45N/AN/AN/AN/A-479.36%N/A
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$2.51N/AN/AN/AN/A10.91%7.47%8/6/2025 (Estimated)

Latest ARTL, NKGN, CASI, and SYBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/16/2025Q1 2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$0.61-$0.69-$0.08-$0.69$7.39 million$6.24 million
5/13/2025Q1 2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$0.78-$4.32-$3.54-$0.72N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/AN/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/A
0.49
0.49
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/A
0.81
0.68
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
3.68
3.68

Institutional Ownership

CompanyInstitutional Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.87%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
22.23%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%

Insider Ownership

CompanyInsider Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.83%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
21.24%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
Synlogic, Inc. stock logo
SYBX
Synlogic
3.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
5550,000542,000Not Optionable
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
18012.30 million9.69 millionOptionable
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A44.95 million40.29 millionNot Optionable
Synlogic, Inc. stock logo
SYBX
Synlogic
8011.70 million11.34 millionOptionable

Recent News About These Companies

Synlogic Reports Q3 2024 Financial Outcomes
Synlogic Reports Third Quarter 2024 Financial Results
Synlogic, Inc. (0A8U.L)
MIN.SG,0P0001I7V6,0 (MIN.SG)
SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
Synlogic Reports Second Quarter 2024 Financial Results
Synlogic Inc.
Synlogic Inc SYBX
Synlogic Flat on Q1 Numbers
Synlogic Reports First Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Artelo Biosciences stock logo

Artelo Biosciences NASDAQ:ARTL

$10.80 -0.24 (-2.13%)
As of 03:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

CASI Pharmaceuticals stock logo

CASI Pharmaceuticals NASDAQ:CASI

$1.33 0.00 (-0.02%)
As of 03:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.30 0.00 (0.00%)
As of 12:47 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.20 0.00 (-0.33%)
As of 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.